Lek d.d.

What Lek d.d. does

Lek d.d. is a Slovenian pharmaceutical company founded in 1946, headquartered in Ljubljana, that develops, produces, and distributes generic pharmaceuticals for customers worldwide. The company employs 251-500 people and serves healthcare providers and pharmacies as its primary customer segment, with a secondary focus on government agencies for strategic partnerships and bilateral trade initiatives.

The company's operations extend beyond core pharmaceutical manufacturing into diversified high-tech sectors, including semiconductor manufacturing operations in Batangas, Philippines, and business internet services. Lek benefits from significant Slovenian government support, having received a 42 million EUR grant in 2025 for high-tech project development, which positions it as a strategically important national enterprise. The company maintains active international market presence in Central Asia (Kazakhstan) and Southeast Asia (Philippines), accessing these markets through bilateral trade channels and government-facilitated partnerships rather than conventional commercial sales channels.

Lek's business model is anchored in pharmaceutical product distribution and manufacturing, with revenue generated through recurring product sales and hardware-related manufacturing operations. The company is privately held with no publicly identified parent company. Its go-to-market relies heavily on government-backed bilateral trade relationships and participation in international business forums, suggesting a distribution model that leverages state-level diplomatic and economic relationships rather than direct consumer marketing. Recent evidence indicates a strategic pivot toward high-tech capabilities funded by government grants, potentially transforming the company from a pure-play generics manufacturer into a diversified pharmaceutical-technology enterprise.

Name

Lek d.d.

Legal name

Lek d.d.

Website

https://tabijastrology.in

Company type

Private

Founded year

1946

Operating status

Operating

Headcount range

251–500 employees

Short description

Lek d.d. is a Slovenian pharmaceutical company founded in 1946 that develops, produces, and distributes generic pharmaceuticals for healthcare providers internationally, with operations spanning Slovenia, Kazakhstan, and the Philippines, supported by government-backed bilateral trade channels and high-tech manufacturing initiatives.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Biologics development
• Active pharmaceutical ingredients
• Pharmaceutical distribution

Headquarters

HQ city

Ljubljana

HQ country

Slovenia

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical products: Lek d.d. operates as a pharmaceutical company producing and distributing pharmaceutical products internationally across markets including Southeast Asia and Central Asia
2. Manufacturing operations: Operations in semiconductor manufacturing in Batangas, Philippines and business internet services indicating diversified manufacturing capabilities

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Lek d.d. develops, produces, and distributes generic pharmaceutical products for international markets, with manufacturing operations based in Slovenia and adjacent semiconductor manufacturing activities in the Philippines. The company maintains active market operations in Kazakhstan and participates in bilateral pharmaceutical trade across Southeast Asia and Central Asia.

Product overview

Lek d.d. is a Slovenian pharmaceutical and healthcare company with a high-tech project portfolio. The company operates in semiconductor manufacturing in the Philippines and maintains business activities in Kazakhstan's market. The company has received Slovenian government support through a grant of up to 42 million euros for its high-tech initiatives. No specific branded products, modules, or named offerings are documented in the available sources.

Differentiator

Problem solved

Functional benefit

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered minor.

• Philippine Government AgenciesminorStrategic or Co-development PartnerMultiple Philippine government agencies are participating in a two-day matchmaking session with Slovenian companies including Lek, focusing on science-to-business collaboration, decarbonization, and AI in disaster management.
• Republic of KazakhstanminorStrategic or Co-development PartnerLek is already active in the Kazakh market alongside other Slovenian companies including Iskra, Gorenje, and Krka. Presidents of both countries discussed expanded economic cooperation at the Kazakhstan-Slovenia Business Forum.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Polpharma: Polpharma is one of the largest Polish generic pharmaceutical manufacturers with active presence in Central Asian markets. Comparable in product category, generics manufacturing model, and regional expansion strategy.
• Gedeon Richter: Gedeon Richter is a Hungarian-headquartered generic and specialty pharmaceutical manufacturer with deep Central/Eastern European presence. Comparable in scale, product focus (generics + biosimilars), and regional market strategy.
• Stada Arzneimittel: Stada is a European-focused generic and specialty pharmaceutical manufacturer headquartered in Germany with strong Central/Eastern European presence. Comparable product mix (generics + biosimilars) and similar regional market focus to Lek d.d.
• Krka: Krka is a Slovenian-headquartered generic pharmaceutical manufacturer with similar product profile, geographic reach across Central/Eastern Europe, and an international expansion model. It is co-mentioned with Lek d.d. in the Kazakhstan–Slovenia Business Forum, making it the closest direct peer.
• Zentiva: Zentiva is a European generics manufacturer headquartered in Prague with strong presence in Central/Eastern Europe. Comparable product portfolio and regional market focus to Lek d.d.

Broad incumbents

• Sandoz: Sandoz is a global leader in generics and biosimilars with multi-billion-dollar scale; historically Lek d.d. was a Sandoz subsidiary. Comparable in product category (generics + biologics manufacturing) but vastly larger and broader in geographic reach.
• Viatris: Viatris is a global pharmaceutical company formed from the Mylan–Upjohn combination with a large generics and biosimilars portfolio. Comparable in product category and target customers (pharmacy supply, public health) but at significantly larger scale.
• Aurobindo Pharma: Aurobindo is one of the largest Indian generic pharmaceutical manufacturers with significant global supply presence. Comparable in generics manufacturing business model but operates at vastly larger scale and lower cost base.
• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with extensive specialty and biosimilar offerings. Comparable in core generics manufacturing business model but operates at far greater global scale.

Emerging players

• Alvotech: Alvotech is an Iceland-based biosimilars-focused manufacturer with biologics technical capabilities. Comparable in biologics/specialty manufacturing focus but focused exclusively on biosimilars rather than broad generics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/sandoz_global
• Facebookfacebook.com/sandozglobal
• LinkedInlinkedin.com/company/lek-pharmaceuticals-d-d-

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lek d.d.